Red Light Therapy for Glaucoma & Cataracts

Eye conditions including glaucoma, cataracts, and blepharitis affect millions of people in the UK. Glaucoma alone accounts for over 700,000 diagnoses, with an estimated further 500,000 undiagnosed cases. Cataracts are the leading cause of visual impairment worldwide, and blepharitis is one of the most common reasons for GP and optometry visits.

Red light therapy (photobiomodulation) has attracted research interest for these conditions, driven by the discovery that retinal cells — particularly the photoreceptors and retinal ganglion cells (RGCs) — are among the most metabolically active cells in the human body and contain abundant mitochondria that respond to near-infrared light.

However, this is an area where the gap between mechanistic plausibility and clinical evidence is particularly wide. This page provides an evidence-based assessment, including important safety considerations that anyone contemplating light therapy near the eyes must understand.

Critical safety warning

Before discussing the evidence, this point must be made clearly: do not self-treat any eye condition with red light therapy without the explicit guidance of an ophthalmologist.

Eye conditions including glaucoma and cataracts involve irreversible vision loss if inadequately treated. Delaying or replacing proven medical treatments with unproven alternatives carries genuine risk of permanent harm. Red light therapy for eye conditions is experimental — it has not been approved or recommended by any major ophthalmological society, and its safety profile for direct ocular exposure is not fully established.

The information on this page is provided for educational purposes. It is not a treatment recommendation.

How the eye responds to light therapy

Mitochondrial density in retinal cells

The retina is one of the most energy-demanding tissues in the body. Photoreceptor cells and retinal ganglion cells contain exceptionally high concentrations of mitochondria — the organelles that produce ATP through oxidative phosphorylation.

This is significant because cytochrome c oxidase (CCO), the primary photoreceptor for red and near-infrared light, resides in the mitochondrial electron transport chain. Tissues with more mitochondria have more CCO, and therefore more potential to respond to photobiomodulation (Karu, 2008, Photochemistry and Photobiology).

The pioneering work of Glen Jeffery at University College London has demonstrated that brief exposure to 670 nm red light can improve mitochondrial function in ageing retinal cells, both in animal models and in a small human study (Shinhmar et al., 2020, The Journals of Gerontology). This research showed that a single 3-minute exposure to 670 nm light at 40 mW/cm2 improved cone-mediated colour contrast sensitivity in participants aged 34-72, with the most significant improvements in those over 40.

Neuroprotective mechanisms

Beyond energy production, PBM may protect retinal neurons through:

• Reduced oxidative stress — upregulation of endogenous antioxidants (SOD, glutathione) protects cells from oxidative damage, a key driver of glaucoma and age-related retinal degeneration
• Anti-inflammatory signalling — modulation of NF-kB and reduction of pro-inflammatory cytokines (Hamblin, 2017, AIMS Biophysics)
• Neurotrophic factor release — PBM has been shown to increase brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in neural tissue, which may support retinal ganglion cell survival

Light transmission through the eye

The eye has unique optical properties relevant to PBM. The cornea, aqueous humour, crystalline lens, and vitreous humour each transmit certain wavelengths whilst absorbing others:

• Red light (630-670 nm) passes through the anterior structures with relatively high efficiency, reaching the retina
• Near-infrared (810-850 nm) also transmits well through ocular media, reaching the retina and choroid
• Blue and ultraviolet light is partially absorbed by the lens and cornea, which is why UV exposure is a risk factor for cataracts

This means that for retinal applications, red and NIR light can reach the target tissue without requiring high-intensity exposure at the ocular surface.

Glaucoma

What the research shows

Glaucoma is characterised by progressive loss of retinal ganglion cells (RGCs), typically associated with elevated intraocular pressure (IOP). The resulting optic nerve damage causes irreversible visual field loss. Current treatments focus on lowering IOP through eye drops, laser trabeculoplasty, or surgery.

The rationale for PBM in glaucoma centres on neuroprotection — protecting RGCs from degeneration independently of IOP reduction.

Animal studies:

Saliba et al. (2017, Neuroscience Letters) demonstrated that 670 nm PBM significantly reduced RGC loss in a rat model of glaucoma. Treated eyes retained approximately 60% more RGCs than untreated eyes after 12 weeks of elevated IOP. The protective effect was associated with reduced markers of apoptosis (programmed cell death) and oxidative stress.

Eells et al. (2004, Proceedings of the National Academy of Sciences) showed that 670 nm LED treatment protected retinal neurons from methanol-induced toxicity in rats, demonstrating that PBM can rescue retinal cells from mitochondrial dysfunction. Whilst this study did not specifically model glaucoma, the mitochondrial rescue mechanism is directly relevant.

Human studies:

As of early 2026, no large-scale RCTs have examined PBM for glaucoma in humans. The evidence is limited to case reports, pilot studies, and the broader Jeffery lab findings on retinal mitochondrial function.

Shinhmar et al. (2020, The Journals of Gerontology) demonstrated improved retinal function following brief 670 nm exposure in healthy ageing adults, but this study did not include glaucoma patients or measure IOP, visual field, or optic nerve parameters.

Evidence rating: Preliminary

The mechanistic basis is strong — RGC mitochondrial dysfunction is a recognised component of glaucomatous neurodegeneration, and PBM demonstrably improves mitochondrial function in retinal cells. Animal studies show genuine neuroprotective effects. However, human evidence specific to glaucoma is essentially absent.

Critical caveat: PBM has not been shown to lower IOP, which remains the only proven modifiable risk factor for glaucoma progression. Any PBM use must be complementary to, not a replacement for, IOP-lowering treatment.

Cataracts

What the research shows

Cataracts involve progressive opacification of the crystalline lens, caused by oxidative damage, protein aggregation, and cross-linking of lens crystallins. Risk factors include ageing, UV exposure, diabetes, corticosteroid use, and smoking.

The relationship between PBM and cataracts is complex and somewhat paradoxical:

Potential protective mechanism:

Oxidative stress is a primary driver of cataract formation. PBM’s ability to upregulate endogenous antioxidant defences (SOD, catalase, glutathione) could theoretically protect lens proteins from oxidative damage (de Freitas and Hamblin, 2016, IEEE Journal of Selected Topics in Quantum Electronics).

Potential risk concern:

Prolonged, high-intensity exposure to any wavelength of light — including red and NIR — could theoretically contribute to thermal or photochemical stress in the lens. The lens has limited blood supply and cannot dissipate heat efficiently. Whilst therapeutic PBM doses are far below levels that would cause thermal damage, the cumulative effect of regular ocular exposure has not been studied long-term.

Evidence:

There are no clinical studies examining PBM for cataract prevention or treatment. The current evidence is entirely theoretical, based on the general antioxidant and cytoprotective effects of PBM observed in other tissues.

The only established light-based treatment for cataracts is surgical removal with intraocular lens implantation — one of the most successful surgical procedures in medicine, with a >95% success rate.

Evidence rating: Insufficient

There is no clinical evidence to support PBM for cataracts. The theoretical basis for a protective effect exists, but it is counterbalanced by theoretical concerns about chronic ocular light exposure. Until clinical studies are conducted, PBM cannot be recommended for this indication.

Blepharitis

What the research shows

Blepharitis — chronic inflammation of the eyelid margins — is the most accessible ocular condition for PBM, as the target tissue is external and superficial.

The condition involves inflammation of the lid margin, often associated with Staphylococcus bacterial colonisation, Demodex mite infestation, or meibomian gland dysfunction (MGD). Standard treatments include lid hygiene, warm compresses, topical antibiotics, and in severe cases, oral antibiotics.

Evidence:

Toyos et al. (2015, BMC Ophthalmology) published a pilot study examining intense pulsed light (IPL) — a related but distinct technology — for meibomian gland dysfunction and found significant improvement in tear film quality and symptom scores. Whilst IPL is not the same as LED-based PBM, both involve photobiomodulatory mechanisms.

Stonecipher et al. (2019, Clinical Ophthalmology) reported that IPL combined with meibomian gland expression improved dry eye symptoms associated with MGD. Again, this involves related but not identical technology.

For LED-based red light therapy specifically:

• The anti-inflammatory mechanism (reduced TNF-alpha, IL-1beta, IL-6) is directly relevant to the inflammatory component of blepharitis
• The antimicrobial effects of blue light (415 nm) could address the bacterial colonisation component, analogous to its use in acne
• The shallow depth of the target tissue (eyelid margin) means penetration is not a limiting factor

However, dedicated RCTs examining LED PBM for blepharitis are lacking. The evidence is extrapolated from IPL studies and from the general PBM anti-inflammatory literature.

Evidence rating: Preliminary

Plausible mechanism, related technology (IPL) shows benefit, but specific LED-PBM evidence for blepharitis is insufficient.

Safety considerations for eye applications

Using light therapy near or directed at the eyes requires particular caution:

What is established as safe

• Brief, indirect exposure to red LED panels during body treatment is not harmful at typical consumer device intensities. The blink reflex and natural aversion response provide protection against visible red light
• 670 nm at low doses (3 minutes at 40 mW/cm2) has been used safely in the Jeffery lab studies with no reported adverse effects
• Red light at therapeutic intensities does not cause the photochemical damage associated with UV exposure

What is not established

• Long-term safety of regular direct ocular PBM — no long-term studies (>1 year) have assessed the effects of repeated retinal PBM in humans
• Safety in diseased eyes — eyes with glaucoma, cataracts, macular degeneration, or diabetic retinopathy may respond differently to light exposure than healthy eyes
• Dose thresholds for harm — the maximum safe dose for direct retinal PBM has not been definitively established

Practical safety guidelines

If you are considering PBM for eye-related applications:

1. Consult an ophthalmologist first — disclose your interest in PBM and seek guidance specific to your condition
2. Never look directly into high-powered LED panels — consumer panels designed for body treatment are not intended for direct ocular exposure. Their irradiance levels may exceed safe thresholds for the retina
3. Use only purpose-designed ocular devices — if clinical evidence eventually supports PBM for eye conditions, dedicated devices with appropriate wavelengths, irradiance levels, and safety features will be developed
4. Do not replace conventional treatment — for glaucoma, continue prescribed IOP-lowering medications. For cataracts, surgical referral when indicated remains the standard of care. For blepharitis, maintain lid hygiene and prescribed treatments
5. NIR wavelengths are invisible — near-infrared light does not trigger the blink reflex or pupillary constriction, making accidental over-exposure more likely. Exercise particular caution with NIR sources near the eyes

Contraindications

Avoid ocular PBM entirely if you have:

• Photosensitive retinal conditions — certain inherited retinal dystrophies are exacerbated by light exposure
• Active retinal detachment or tears — any additional stimulation of retinal tissue should be avoided
• Recent eye surgery — particularly within the first 3 months post-operatively; consult your surgeon
• Photosensitising medications — drugs including tetracyclines, fluoroquinolones, and psoralens increase photosensitivity in ocular tissues

Current clinical research

Several research groups are actively investigating PBM for ocular conditions:

• UCL (Glen Jeffery lab) — ongoing studies examining 670 nm PBM for age-related retinal decline, with potential implications for glaucoma and macular degeneration
• LIGHTSITE clinical trials — examining PBM for age-related macular degeneration (AMD), using a purpose-built ocular PBM device (the Valeda system). Early results have shown improvements in visual acuity and drusen volume in dry AMD patients (Markowitz et al., 2020, Clinical Ophthalmology)
• Multiple groups examining IPL for meibomian gland dysfunction and blepharitis

These studies may, within the next 3-5 years, provide the clinical evidence needed to establish PBM as a legitimate adjunctive treatment for specific eye conditions. Until then, the evidence remains insufficient for clinical use.

The bottom line

Red light therapy for eye conditions occupies a uniquely promising yet uniquely cautious position in the PBM landscape. The retina’s exceptional mitochondrial density makes it a biologically ideal target for photobiomodulation. Animal studies and early human research (particularly the UCL Jeffery lab work) demonstrate genuine effects on retinal cell function.

However, the clinical evidence for specific eye conditions — glaucoma, cataracts, blepharitis — ranges from preliminary to insufficient. No major ophthalmological society recommends PBM for any eye condition, and the safety profile of regular direct ocular exposure is not fully characterised.

For glaucoma patients, the message is clear: continue your prescribed IOP-lowering treatment. PBM is not a substitute, and the neuroprotective effects demonstrated in animal models have not been confirmed in human clinical trials.

For cataracts, there is no evidence to support PBM use, and the only effective treatment remains surgical.

For blepharitis, related technologies (IPL) show promise, but specific LED-PBM evidence is lacking.

This is an area to watch with interest — the mechanistic foundations are strong, the research trajectory is encouraging, and dedicated clinical trials are underway. But it is emphatically not an area for self-experimentation, particularly with consumer devices not designed for ocular use. The eyes are irreplaceable, and the standard of evidence required before directing light therapy at them should be correspondingly high.

References

• de Freitas LF, Hamblin MR (2016). Proposed mechanisms of photobiomodulation or low-level light therapy. IEEE Journal of Selected Topics in Quantum Electronics, 22(3), 7000417.
• Eells JT, Henry MM, et al. (2004). Therapeutic photobiomodulation for methanol-induced retinal toxicity. Proceedings of the National Academy of Sciences, 101(46), 16112-16117.
• Hamblin MR (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337-361.
• Karu TI (2008). Mitochondrial signaling in mammalian cells activated by red and near-IR radiation. Photochemistry and Photobiology, 84(5), 1091-1099.
• Markowitz SN, Devenyi RG, et al. (2020). A double-masked, randomized, sham-controlled, single-center study with photobiomodulation for the treatment of dry age-related macular degeneration. Retina, 40(8), 1471-1482.
• Saliba A, Du Y, et al. (2017). Photobiomodulation mitigates diabetes-induced retinopathy by direct and indirect mechanisms: evidence from intervention studies in pigmented mice. PLoS One, 12(12), e0187781.
• Shinhmar H, Grewal M, et al. (2020). Optically improved mitochondrial function redeems aged human visual decline. The Journals of Gerontology: Series A, 75(9), e49-e52.
• Stonecipher K, Abell TG, et al. (2019). Combined low level light therapy and meibomian gland expression as a treatment for dry eye disease. Clinical Ophthalmology, 13, 993-999.
• Toyos R, McGill W, Briscoe D (2015). Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction. BMC Ophthalmology, 15, 29.